Literature DB >> 29029707

Epidemiology, Pathophysiology, Stratification, and Natural History of Pulmonary Embolism.

Nicholas J Giordano1, Paul S Jansson2, Michael N Young3, Kaitlin A Hagan4, Christopher Kabrhel5.   

Abstract

Pulmonary embolism (PE) is a common and potentially fatal form of venous thromboembolism that can be challenging to diagnose and manage. PE occurs when there is obstruction of the pulmonary vasculature and is a common cause of morbidity and mortality in the United States. A combination of acquired and inherited factors may contribute to the development of this disease and should be considered, since they have implications for both susceptibility to PE and treatment. Patients with suspected PE should be evaluated efficiently to diagnose and administer therapy as soon as possible, but the presentation of PE is variable and nonspecific so diagnosis is challenging. PE can range from small, asymptomatic blood clots to large emboli that can occlude the pulmonary arteries causing sudden cardiovascular collapse and death. Thus, risk stratification is critical to both the prognosis and management of acute PE. In this review, we discuss the epidemiology, risk factors, pathophysiology, and natural history of PE and deep vein thrombosis.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  DVT; Natural History; PE; VTE

Mesh:

Year:  2017        PMID: 29029707     DOI: 10.1053/j.tvir.2017.07.002

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  30 in total

1.  Autophagy genes CCL2 and MYC are considered as potential biomarkers for pulmonary embolism.

Authors:  Xuehui Zhang; Naibin Yang; Lijiang Shao; Xuxia Chen; Xueqin Chen
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Acute Pulmonary Embolism: Contemporary Approach to Diagnosis, Risk-Stratification, and Management.

Authors:  Tahir Tak; Swetha Karturi; Umesh Sharma; Lee Eckstein; Joseph T Poterucha; Yader Sandoval
Journal:  Int J Angiol       Date:  2019-07-05

3.  Predictive Value of Circulating microRNA-134 Levels for Early Diagnosis of Acute Pulmonary Embolism: Meta-analysis.

Authors:  Yu Liu; Ming Xie; Xiaoli Gao; Ran Liu
Journal:  J Cardiovasc Transl Res       Date:  2021-01-06       Impact factor: 4.132

Review 4.  The effect of emerging tobacco related products and their toxic constituents on thrombosis.

Authors:  Ahmed B Alarabi; Patricia A Lozano; Fadi T Khasawneh; Fatima Z Alshbool
Journal:  Life Sci       Date:  2021-12-23       Impact factor: 6.780

5.  Effect of varying computed tomography acquisition and reconstruction parameters on semi-automated clot volume quantification.

Authors:  Audrey E Kaufman; Alison N Pruzan; Ching Hsu; Sarayu Ramachandran; Adam Jacobi; Zahi A Fayad; Venkatesh Mani
Journal:  World J Radiol       Date:  2018-03-28

6.  Dissimilarity in the Frequency of Venous Thromboembolism Risk Factors among Studies, a Commentary.

Authors:  Meghdad Sedaghat; Mahsa Soltani; Mehrdad Solooki
Journal:  Emerg (Tehran)       Date:  2018-01-18

7.  Venous Thromboembolism While on Anticoagulation With Apixaban.

Authors:  Farah Mazahreh; Fuad Habash; Angel López-Candales
Journal:  Cureus       Date:  2021-05-23

8.  Retrievable celect™ filter placement in the superior vena cava: A case report.

Authors:  Tulio Fabiano De Oliveira Leite; Thiago Oliveira E Silva; Osvaldo Ignacio Pereira; Francisco Cesar Carnevale
Journal:  Int J Surg Case Rep       Date:  2020-06-29

9.  Correlating computed tomography pulmonary angiography signs of right ventricular strain in pulmonary embolisms to clinical outcomes.

Authors:  Jay Karri; Tiffany Truong; Joseph Hasapes; Daniel Ocazionez Trujillo; Steven Chua; Kaustubh Shiralkar; Gabriel Aisenberg
Journal:  Ann Thorac Med       Date:  2020-04-03       Impact factor: 2.219

10.  Predictive value of lymphocyte to monocyte ratio and monocyte to high-density lipoprotein ratio for acute deep vein thrombosis after total joint arthroplasty: a retrospective study.

Authors:  Xiaobo Zhu; Yao Yao; Chen Yao; Qing Jiang
Journal:  J Orthop Surg Res       Date:  2018-08-24       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.